RU2017104909A3 - - Google Patents
Download PDFInfo
- Publication number
- RU2017104909A3 RU2017104909A3 RU2017104909A RU2017104909A RU2017104909A3 RU 2017104909 A3 RU2017104909 A3 RU 2017104909A3 RU 2017104909 A RU2017104909 A RU 2017104909A RU 2017104909 A RU2017104909 A RU 2017104909A RU 2017104909 A3 RU2017104909 A3 RU 2017104909A3
- Authority
- RU
- Russia
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K33/00—Medicinal preparations containing inorganic active ingredients
- A61K33/24—Heavy metals; Compounds thereof
- A61K33/244—Lanthanides; Compounds thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/337—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having four-membered rings, e.g. taxol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
- A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
- A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
- A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
- A61K31/7068—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines having oxo groups directly attached to the pyrimidine ring, e.g. cytidine, cytidylic acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K33/00—Medicinal preparations containing inorganic active ingredients
- A61K33/24—Heavy metals; Compounds thereof
- A61K33/243—Platinum; Compounds thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0014—Skin, i.e. galenical aspects of topical compositions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/10—Dispersions; Emulsions
- A61K9/107—Emulsions ; Emulsion preconcentrates; Micelles
- A61K9/1075—Microemulsions or submicron emulsions; Preconcentrates or solids thereof; Micelles, e.g. made of phospholipids or block copolymers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Epidemiology (AREA)
- Inorganic Chemistry (AREA)
- Molecular Biology (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Dermatology (AREA)
- Biophysics (AREA)
- Dispersion Chemistry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicinal Preparation (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201462025861P | 2014-07-17 | 2014-07-17 | |
| US62/025,861 | 2014-07-17 | ||
| PCT/US2015/040869 WO2016011328A1 (en) | 2014-07-17 | 2015-07-17 | Treatment of cancer with a combination of radiation, cerium oxide nanoparticles, and a chemotherapeutic agent |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| RU2019133284A Division RU2019133284A (ru) | 2014-07-17 | 2015-07-17 | Лечение рака комбинацией лучевой терапии, наночастиц оксида церия и химиотерапевтического средства |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| RU2017104909A RU2017104909A (ru) | 2018-08-17 |
| RU2017104909A3 true RU2017104909A3 (enExample) | 2019-01-28 |
| RU2704811C2 RU2704811C2 (ru) | 2019-10-31 |
Family
ID=55079076
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| RU2017104909A RU2704811C2 (ru) | 2014-07-17 | 2015-07-17 | Лечение рака комбинацией лучевой терапии, наночастиц оксида церия и химиотерапевтического средства |
| RU2019133284A RU2019133284A (ru) | 2014-07-17 | 2015-07-17 | Лечение рака комбинацией лучевой терапии, наночастиц оксида церия и химиотерапевтического средства |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| RU2019133284A RU2019133284A (ru) | 2014-07-17 | 2015-07-17 | Лечение рака комбинацией лучевой терапии, наночастиц оксида церия и химиотерапевтического средства |
Country Status (9)
| Country | Link |
|---|---|
| EP (2) | EP3628308A1 (enExample) |
| JP (2) | JP6706255B2 (enExample) |
| CN (2) | CN111184733A (enExample) |
| AU (1) | AU2015289504B2 (enExample) |
| BR (1) | BR112017000800A8 (enExample) |
| CA (1) | CA2955384C (enExample) |
| MX (1) | MX387363B (enExample) |
| RU (2) | RU2704811C2 (enExample) |
| WO (1) | WO2016011328A1 (enExample) |
Families Citing this family (21)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US10512761B2 (en) | 2009-12-02 | 2019-12-24 | Renovorx, Inc. | Methods for delivery of therapeutic materials to treat pancreatic cancer |
| WO2014197362A1 (en) | 2013-06-03 | 2014-12-11 | Ramtin Agah | Devices, methods and kits for delivery of therapeutic materials to a pancreas |
| AU2015289504B2 (en) * | 2014-07-17 | 2020-12-17 | BioCurity Pharmaceuticals Inc. | Treatment of cancer with a combination of radiation, cerium oxide nanoparticles, and a chemotherapeutic agent |
| WO2017174437A1 (en) * | 2016-04-05 | 2017-10-12 | Hospital Clínic De Barcelona | Ceria nanoparticles for use in the treatment of hepatocellular carcinoma |
| WO2018134254A1 (en) | 2017-01-17 | 2018-07-26 | Heparegenix Gmbh | Protein kinase inhibitors for promoting liver regeneration or reducing or preventing hepatocyte death |
| CA3063115A1 (en) * | 2017-04-12 | 2018-10-18 | Vikash J. BHAGWANDIN | Compositions, packaged pharmaceuticals, and methods of using posaconazole for the sensitization of resistant tumors |
| AU2018258663B2 (en) * | 2017-04-28 | 2022-08-04 | Seagen Inc. | Treatment of HER2 positive cancers |
| US12290564B2 (en) | 2017-05-18 | 2025-05-06 | Renovorx, Inc. | Methods and apparatuses for treating tumors |
| US10695543B2 (en) | 2017-05-18 | 2020-06-30 | Renovorx, Inc. | Methods for treating cancerous tumors |
| US11052224B2 (en) | 2017-05-18 | 2021-07-06 | Renovorx, Inc. | Methods for treating cancerous tumors |
| WO2019124603A1 (ko) * | 2017-12-22 | 2019-06-27 | 경상대학교병원 | Iwr-1을 유효성분으로 함유하는 켈로이드 예방 또는 치료용 조성물 |
| KR102102535B1 (ko) * | 2018-07-26 | 2020-04-21 | 서울대학교산학협력단 | 방사선 보호 나노입자 |
| WO2020069292A1 (en) * | 2018-09-28 | 2020-04-02 | The Regents Of The University Of Colorado, A Body Corporate | Methods for preventing and treating pulmonary inflammation and fibrosis |
| RU2699670C1 (ru) * | 2018-11-16 | 2019-09-09 | Объединенный Институт Ядерных Исследований (Оияи) | Способ повышения частоты образования двунитевых разрывов днк в клетках человека при действии ионизирующих излучений в условиях влияния радиомодификаторов |
| CN115996633A (zh) * | 2020-04-30 | 2023-04-21 | 中佛罗里达大学研究基金会 | 消毒用可分配的纳米颗粒基组合物 |
| JP2024531479A (ja) | 2021-08-27 | 2024-08-29 | アセンタウィッツ ファーマシューティカルズ リミテッド | 凍結乾燥製剤溶液および凍結乾燥製剤、ならびにそれらの方法および使用 |
| JP7762796B2 (ja) | 2021-08-27 | 2025-10-30 | アセンタウィッツ ファーマシューティカルズ リミテッド | Ｐａｒｐ阻害剤に耐性のある患者のｔｈ－３０２による治療 |
| US20250186468A1 (en) | 2022-03-15 | 2025-06-12 | Ascentawits Pharmaceuticals, Ltd. | Method for treating patient with brca-mutated cancer |
| EP4509127A1 (en) | 2022-04-15 | 2025-02-19 | Ascentawits Pharmaceuticals, Ltd. | Method for treating cancer by using th-302 alone or in combination with parp inhibitor |
| EP4529926A1 (en) | 2022-05-23 | 2025-04-02 | Ascentawits Pharmaceuticals, Ltd. | Method for treating cancer by combining alkylating agent prodrug and cell cycle inhibitor |
| CN119894521A (zh) | 2022-09-22 | 2025-04-25 | 深圳艾欣达伟医药科技有限公司 | 乏氧激活的化合物在制备治疗癌症患者的药物中的用途 |
Family Cites Families (15)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6099798A (en) | 1997-10-31 | 2000-08-08 | Nanogram Corp. | Ultraviolet light block and photocatalytic materials |
| TWI323662B (en) * | 2002-11-15 | 2010-04-21 | Telik Inc | Combination cancer therapy with a gst-activated anticancer compound and another anticancer therapy |
| EP1904072A4 (en) * | 2005-06-27 | 2009-06-17 | Edward Via Virginia College Of | ANTI-INFLAMMATORY, RADIOPROTECTIVE CERTIFICATE OXIDE NANOPARTICLE CAPACITIES AND ENHANCING LONGEVITY |
| CA2710377A1 (en) * | 2007-12-27 | 2009-07-09 | Infinity Pharmaceuticals, Inc. | Therapeutic cancer treatments |
| EP2288258A4 (en) * | 2008-04-25 | 2012-10-31 | Univ Oklahoma | INHIBITION OF NEOVASCULARIZATION BY CERIUM OXIDE NANOPARTICLES |
| US20100015042A1 (en) * | 2008-07-03 | 2010-01-21 | Ramot At Tel Aviv University Ltd. | Combine radiation therapy and chemotherapy for treating cancer |
| GB0921596D0 (en) * | 2009-12-09 | 2010-01-27 | Isis Innovation | Particles for the treatment of cancer in combination with radiotherapy |
| CN102933258A (zh) * | 2010-03-01 | 2013-02-13 | 因特奥普医药公司 | 与含氧量低的细胞敏化剂联用的放疗 |
| US20120251496A1 (en) * | 2011-03-31 | 2012-10-04 | Telik, Inc. | Ezatiostat for treating multiple myeloma |
| CA2869554A1 (en) * | 2012-04-04 | 2013-10-10 | Duke University | Methods of using cerium oxide nanoparticles to mitigate or protect against radiation injury |
| JP6174692B2 (ja) * | 2012-06-13 | 2017-08-02 | セリオン エンタープライジズ リミテッド ライアビリティ カンパニー | 酸化ストレスの処置のためのナノセリア |
| EP2928877B1 (en) * | 2012-12-06 | 2020-01-22 | Merck Sharp & Dohme Corp. | Disulfide masked prodrug compositions and methods |
| WO2015164780A1 (en) * | 2014-04-25 | 2015-10-29 | The Regents Of The University Of Michigan | Nanoparticle therapy in cancer |
| AU2015289504B2 (en) * | 2014-07-17 | 2020-12-17 | BioCurity Pharmaceuticals Inc. | Treatment of cancer with a combination of radiation, cerium oxide nanoparticles, and a chemotherapeutic agent |
| GB201506381D0 (en) * | 2015-04-15 | 2015-05-27 | Isis Innovation | Embolization particle |
-
2015
- 2015-07-17 AU AU2015289504A patent/AU2015289504B2/en active Active
- 2015-07-17 BR BR112017000800A patent/BR112017000800A8/pt not_active Application Discontinuation
- 2015-07-17 MX MX2017000578A patent/MX387363B/es unknown
- 2015-07-17 RU RU2017104909A patent/RU2704811C2/ru active
- 2015-07-17 CN CN201911066034.XA patent/CN111184733A/zh not_active Withdrawn
- 2015-07-17 CN CN201580038961.4A patent/CN106604719B/zh active Active
- 2015-07-17 JP JP2017523191A patent/JP6706255B2/ja active Active
- 2015-07-17 RU RU2019133284A patent/RU2019133284A/ru unknown
- 2015-07-17 EP EP19207165.2A patent/EP3628308A1/en not_active Withdrawn
- 2015-07-17 CA CA2955384A patent/CA2955384C/en active Active
- 2015-07-17 WO PCT/US2015/040869 patent/WO2016011328A1/en not_active Ceased
- 2015-07-17 EP EP15822181.2A patent/EP3169312B1/en active Active
-
2020
- 2020-05-18 JP JP2020086617A patent/JP2020158507A/ja active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| CN111184733A (zh) | 2020-05-22 |
| EP3628308A1 (en) | 2020-04-01 |
| JP2017521499A (ja) | 2017-08-03 |
| CN106604719B (zh) | 2019-11-26 |
| EP3169312A4 (en) | 2017-12-27 |
| MX2017000578A (es) | 2017-07-20 |
| WO2016011328A1 (en) | 2016-01-21 |
| EP3169312B1 (en) | 2020-09-02 |
| RU2019133284A (ru) | 2019-12-05 |
| CA2955384A1 (en) | 2016-01-21 |
| CA2955384C (en) | 2024-03-12 |
| BR112017000800A8 (pt) | 2023-04-25 |
| JP2020158507A (ja) | 2020-10-01 |
| EP3169312A1 (en) | 2017-05-24 |
| AU2015289504A1 (en) | 2017-02-23 |
| RU2704811C2 (ru) | 2019-10-31 |
| CN106604719A (zh) | 2017-04-26 |
| RU2017104909A (ru) | 2018-08-17 |
| JP6706255B2 (ja) | 2020-06-03 |
| MX387363B (es) | 2025-03-18 |
| AU2015289504B2 (en) | 2020-12-17 |
| BR112017000800A2 (pt) | 2018-07-03 |
Similar Documents
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| HZ9A | Changing address for correspondence with an applicant |